BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32089294)

  • 21. Nitrogen mustard revisited.
    Knobler R
    Br J Dermatol; 2014 Mar; 170(3):495. PubMed ID: 24617430
    [No Abstract]   [Full Text] [Related]  

  • 22. Topical mechlorethamine in the treatment of mycosis fungoides.
    Silver SE
    J Am Acad Dermatol; 1992 Nov; 27(5 Pt 1):786-7. PubMed ID: 1430412
    [No Abstract]   [Full Text] [Related]  

  • 23. Topical mechlorethamine. Cutaneous changes in patients with mycosis fungoides after its administration.
    Price NM
    Arch Dermatol; 1977 Oct; 113(10):1387-9. PubMed ID: 911166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical chemotherapy of mycosis fungoides.
    Grekin DA; Zackheim HS; Epstein EH
    Cutis; 1979 Nov; 24(5):543-6. PubMed ID: 520032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local bullous reaction to topical mechlorethamine (mustine).
    Goday JJ; Aguirre A; Ratón JA; Díaz-Pérez JL
    Contact Dermatitis; 1990 May; 22(5):306-7. PubMed ID: 2143454
    [No Abstract]   [Full Text] [Related]  

  • 26. Frequent low doses of intravenous mechlorethamine for late-stage mycosis fungoides lymphoma.
    Van Scott EJ; Grekin DA; Kalmanson JD; Vonderheid EC; Barry WE
    Cancer; 1975 Nov; 36(5):1613-8. PubMed ID: 1192353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged remission of tumor-stage mycosis fungoides by topical immunotherpay.
    Vonderheid EC; Dellatorre DL; Van Scott EJ
    Arch Dermatol; 1981 Sep; 117(9):586-9. PubMed ID: 6457569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical chemotherapy in mycosis fungoides.
    Grupper C; Durepaire R
    Bull Cancer; 1977; 64(2):323-34. PubMed ID: 912134
    [No Abstract]   [Full Text] [Related]  

  • 29. Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides.
    Delfau-Larue MH; Dalac S; Lepage E; Petrella T; Wechsler J; Farcet JP; Bagot M
    Blood; 1998 Nov; 92(9):3376-80. PubMed ID: 9787176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small malignant melanoma in patients with mycosis fungoides.
    Amichai B; Grunwald MH; Goldstein J; Finkelstein E; Halevy S
    J Eur Acad Dermatol Venereol; 1998 Sep; 11(2):155-7. PubMed ID: 9784043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ichthyosiform pattern: an exceptional presentation of mycosis fungoides.
    Perandones González H; Sánchez Sambucety P; Rodríguez Prieto MÁ
    Int J Dermatol; 2020 Jun; 59(6):730-732. PubMed ID: 31498889
    [No Abstract]   [Full Text] [Related]  

  • 32. Mycosis fungoides plaque stage treated with topical nitrogen mustard with and without attempts at tolerance induction: report from the Scandinavian mycosis fungoides study group.
    Molin L; Thomsen K; Volden G
    Acta Derm Venereol; 1979; 59(1):64-8. PubMed ID: 84470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Responses of mycosis fungoides to intensive external treatment with nitrogen mustard.
    Van Scott EJ; Winters PL
    Arch Dermatol; 1970 Nov; 102(5):507-14. PubMed ID: 5474113
    [No Abstract]   [Full Text] [Related]  

  • 34. Topical mechlorethamine therapy for mycosis fungoides. Proposed schedule to overcome drug resistance.
    Volden G; Molin L; Thomsen K
    Arch Dermatol; 1982 Feb; 118(2):138-9. PubMed ID: 7059219
    [No Abstract]   [Full Text] [Related]  

  • 35. Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review.
    Trager MH; de Clippelé D; Ram-Wolff C; de Masson A; Vignon-Pennamen MD; Battistella M; Michel L; Bagot M; Dobos G
    Acta Derm Venereol; 2020 May; 100(10):adv00158. PubMed ID: 32449779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypopigmented mycosis fungoides: a report of 7 cases and review of the literature.
    Stone ML; Styles AR; Cockerell CJ; Pandya AG
    Cutis; 2001 Feb; 67(2):133-8. PubMed ID: 11236223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma.
    Vonderheid EC; Tan ET; Kantor AF; Shrager L; Micaily B; Van Scott EJ
    J Am Acad Dermatol; 1989 Mar; 20(3):416-28. PubMed ID: 2537348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythema gyratum repens-like eruptions with large cell transformation in a patient with mycosis fungoides.
    Holcomb M; Duvic M; Cutlan J
    Int J Dermatol; 2012 Oct; 51(10):1231-3. PubMed ID: 21726213
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of mycosis fungoides: total-skin electron-beam irradiation vs topical mechlorethamine therapy.
    Hamminga B; Noordijk EM; van Vloten WA
    Arch Dermatol; 1982 Mar; 118(3):150-3. PubMed ID: 7065660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Commentary and update: topical chemotherapy with mechlorethamine for mycosis fungoides.
    Vonderheid EC; Van Scott EJ
    Cleve Clin Q; 1983; 50(2):97-100. PubMed ID: 6640944
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.